A mid-cap biotechnology company committed to building a scientifically strong and financially successful top tier biopharmaceutical organization that discovers, develops and commercializes innovative molecular targeted therapies.
The best Bull and Bear pitches based on recency and number of recommendations.
OSI pharmaceutical is looking to position itself as a specialty player in the oncology market through its drug Tarceva, which has booked global sales worth $650 million in 2006 alone. The company’s partnership with Genetech and Roche to market… More
Once Tarceva becomes obsolete around 2009, this stock is junk. Bad mgmt. Poor upside.
Read the most recent pitches from players about OSIP.DL.
Find the members with the highest scoring picks in OSIP.DL.
See what the Wall Street professionals think, according to their public statements and filings.